|Over a week ago|
Truist starts ImmunoGen at Buy, sees share boost from full approval for Elahere » 07:2811/2111/21/22
Truist analyst Asthika…
Truist analyst Asthika Goonewarden initiated coverage of ImmunoGen with a Buy rating and $10 price target. The stock has reacted negatively to its very recent maiden conditional approval, which suggests that investors are still concerned that the confirmatory trial will fail, but the company is on the home stretch and will ultimately prevail in receiving full approval for Elahere, the analyst tells investors in a research note. This should unshackle ImmunoGen shares, Goonewarden adds, also stating that circumstances have left a second ADC "overlooked".
ImmunoGen names Daniel Char as Senior Vice President and Chief Legal Officer » 06:3411/2111/21/22
Char joins ImmunoGen…
Char joins ImmunoGen (IMGN) from Evelo Biosciences (EVLO) where he served as General Counsel and Secretary providing strategic counsel and operational support on a broad range of business and legal issues, including business development, commercialization, healthcare fraud, and intellectual property.
ImmunoGen initiated with a Buy at Truist » 06:2711/2111/21/22
Truist analyst Asthika…
Truist analyst Asthika Goonewarden initiated coverage of ImmunoGen with a Buy rating and $10 price target.
NeoGenomics, ImmunoGen launche new program for ovarian cancer patients » 09:2411/1811/18/22
NeoGenomics (NEO) launched a novel biomarker testing program for patients with epithelial ovarian cancer, including primary peritoneal or fallopian tube cancers. Through the FR-ASSIST program, sponsored by ImmunoGen, Inc., (IMGN), EOC patients will have access to the FOLR1 IHC CDx test performed by NeoGenomics to measure the expression of a protein called folate receptor alpha. The FR-ASSIST program was launched in conjunction with the recent U.S. Food and Drug Administration's approval of ELAHERE, ImmunoGen's antibody-drug conjugate targeting FRalpha in patients with platinum-resistant EOC. The new testing program is sponsored entirely by ImmunoGen and provides eligible EOC patients with FRalpha-expression testing through NeoGenomics at no cost, regardless of insurance coverage or test results.
ImmunoGen price target raised to $15 from $12 at Canaccord » 07:4511/1611/16/22
Canaccord analyst John…
Canaccord analyst John Newman raised the firm's price target on ImmunoGen to $15 from $12 and keeps a Buy rating on the shares. The analyst said the FDA granted ELAHERE (mirvetuximab soravtansine) accelerated approval two weeks ahead of the 11/28/2022 action date, a major win and milestone for the company.
ImmunoGen price target raised to $20 from $12 at H.C. Wainwright » 06:0311/1611/16/22
H.C. Wainwright analyst…
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on ImmunoGen to $20 from $12 and keeps a Buy rating on the shares after the company received accelerated approval from the FDA for Elahere. The analyst believes ocular toxicities could have limited impact to Elahere's adoption.
ImmunoGen approval 'best case scenario,' says Piper Sandler » 11:0211/1511/15/22
Piper Sandler analyst…
Piper Sandler analyst Joseph Catanzaro views last night's FDA approval of Elahere on an accelerated basis as the "best case scenario" for ImmunoGen. The company received early approval with a broad label, and the FDA reviewing the interim data from the MIRASOL trial was expected, Catanzaro tells investors in a research note. However, without full details on these interim data, it is difficult to speculate on how they ultimately translate to MIRASOL's chances of success, Catanzaro tells investors in a research note. He keeps a Neutral rating on ImmunoGen with a $6 price target.
ImmunoGen price target raised to $9 from $8 at Barclays » 06:2411/1511/15/22
Barclays analyst Peter…
Barclays analyst Peter Lawson raised the firm's price target on ImmunoGen to $9 from $8 and keeps an Overweight rating on the shares following the FDA approval of mirvetuximab. The drug gained a broad label which beat many investor expectations with inclusion of bevacizumab naive patients, Lawson tells investors in a research note.
ImmunoGen announces FDA accelerated approval of ELAHERE » 16:3411/1411/14/22
ImmunoGen announced that…
ImmunoGen announced that the US Food and Drug Administration has granted accelerated approval for ELAHERE for the treatment of adult patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. ELAHERE was approved under FDA's accelerated approval program based on objective response rate and duration of response data from the pivotal SORAYA trial. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial. ELAHERE is a first-in-class ADC directed against FRalpha, a cell-surface protein highly expressed in ovarian cancer, and is the first FDA approved ADC for platinum-resistant disease. "The approval of ELAHERE is significant for patients with FRalpha-positive platinum-resistant ovarian cancer, which is characterized by limited treatment options and poor outcomes," said Ursula Matulonis, MD, Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, Professor of Medicine at the Harvard Medical School, and SORAYA Co-Principal Investigator. "ELAHERE's impressive anti-tumor activity, durability of response, and overall tolerability observed in SORAYA demonstrate the benefit of this new therapeutic option, and I look forward to treating patients with ELAHERE."
Piper maintains 'some skepticism' on accelerated approval of ImmunoGen's mirve » 11:5511/0411/04/22
Piper Sandler analyst…
Piper Sandler analyst Joseph Catanzaro noted that along with reporting Q3 earnings, ImmunoGen management reiterated confidence that mirvetuximab, or "mirve," will be approved on an accelerated basis on or before the upcoming PDUFA deadline of November 28. However, he continues to "maintain some degree of skepticism around the chances of an accelerated approval" given the close proximity of the confirmatory readout and he also sees confirmatory MIRASOL study "as a trial not without risk," Catanzaro tells investors. He keeps a Neutral rating and $6 price target on ImmunoGen shares.